Abstract
Benzodiazepines exert most of their pharmacological effects by a selective facilitation of the postsynaptic actions of GABA1–3. Clinical4,5, behavioural6,7 and electrophysiological8,9 studies have shown reduced drug response following chronic benzo-diazepine administration. We present here electrophysiological evidence for decreased postsynaptic sensitivity to GABA following chronic benzodiazepine administration as measured by the direct iontophoretic application of GABA and serotonin onto serotonergic cells in the midbrain dorsal raphe nucleus (DRN), known to receive GABAergic input8–12. The subsensitivity to GABA was found to be dose dependent and was seen when diazepam administration was three weeks or longer. Further, acute injection of the specific benzodiazepine antagonist13, Ro15–1788, was found to reverse rapidly the decrease in GABA sensitivity observed in chronically diazepam-treated animals without altering GABA sensitivity in vehicle-treated rats. Decreased response to chronic benzodiazepines does not appear to be consistently related to alterations in the number or affinity of receptors for benzodiazepines14. Our studies of radioligand-binding showed a decrease in the ability of GABA to enhance benzodiazepine binding in cerebral cortical mem branes from chronic diazepam-treated animals without significant changes in benzodiazepine binding site density or affinity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Costa, E. & Guidotti, A. A. Rev. Pharmac. Tox. 19, 531–545 (1979).
Haefely, W. et al. In GABA-Neurotransmitters (eds Krogsgaard-Larsen, P., Scheel-Krueger, J. & Kofod H.) 357–375 (Munksgaard, Copenhagen, 1979).
Tallman, J. F., Paul, S. M., Skolnick, P. & Gallager, D. W. Science 207, 274–281 (1980).
Browne, T. R., In Pharmacology of Benzodiazepines (eds Usdin, E., Skolnick, P., Tallman, J., Greenblatt, D. & Paul, S.) 329–337 (Macmillan, London, 1983).
Greenblatt, D. J. & Shader, R. J. Drug Metabolism. Rev. 8, 13–28 (1978).
Rosenberg, H. C. & Chiu, T. H. Eur. J. Pharmac. 70, 453–460 (1981).
Hironaka, T., Fuchino, K. & Fujii, T. Japan J. Pharmac. 33, 95–102 (1983).
Waterhouse, B., Moises, H., Yeh, H., Geller, H. & Woodward, D. J. Pharmac. exp. Ther. (in the press).
Sher, P., Study, R., Mazzetta, J., Barker, J. & Nelson, P. Brain Res. 268, 171–176 (1983).
Gallager, D. Eur. J. Pharmac. 49, 133–143 (1978).
Belin, M. et al. Brain Res. 170, 279–297 (1979).
Nanopoulos, D., Belin, M., Maitre, M., Vincendon, G. & Pujol, J. Brain Res. 232, 375–389 (1982).
Hunkeler, W. et al. Nature 209, 514–516 (1981).
Braestrup, C. & Nielsen, M. In Handbook of Psychopharmacology (eds Iversen L. L., Iversen S. D. & Snyder S. H.) 285–384 (Plenum, New York, 1983).
Andrade, R., VanderMaelen, C. & Aghajanian, G. Eur. J. Pharmac. 291, 161–169 (1983).
Trulson, M., Preussler, D., Howell, G. & Frederickson, C. Neuropharmacology 21, 1045–1050 (1982).
Cumin, R., Bonetti, E., Scherschlicht, R. & Haefely, W. Experientia 38, 833–834 (1982).
Lukas, S. E. & Griffiths, R. R. Science 217, 1161–1163 (1982).
McNicholas, L. & Martin, W. Fedn Proc. 41, 1639 (1982).
Lund, J. Scand. J. clin. Lab. Invest. 41, 275–280 (1981).
Gallager, D. & Tallman, J. Neuropharmacology (in the press).
Braestrup, C. & Nielsen, M. Adv. Biosci. 31, 221–227 (1981).
Massotti, M., Alleva, F. R., Balazs, T. & Guidotti, A. Neuropharmacology 19, 951–956 (1980).
Braestrup, C., Schmiechen, R., Neef, G., Nielsen, M. & Petersen, E. N. Science 216, 1241–1243 (1982).
Costa, E., Corda, M., Epstein, B., Forchetti, C. & Guidotti, A. In Benzodiazepines: Molecular Biology to Clinical Practice (ed. Costa, E.) 117–146 (Raven, New York, 1983).
Olsen, R. W. A. Rev. Pharmac. Tox. 22, 45–77 (1982).
Tallman, J. F., Thomas, J. W. & Gallager, D. W. Nature 274, 383–385 (1978).
Gallager, D. W. & Bunney, W. E. Naunyn–Schmiedeberg's Arch. Pharmac. 307, 129–133 (1979).
Lowry, O. H., Rosebrough, M. J., Farr, A. L. & Randall, R. L. J. biol. Chem. 193, 265–275 (1951).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gallager, D., Lakoski, J., Gonsalves, S. et al. Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity. Nature 308, 74–77 (1984). https://doi.org/10.1038/308074a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/308074a0
This article is cited by
-
New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System
CNS Drugs (2023)
-
NMDA Receptors and NO:cGMP Signaling Pathway Mediate the Diazepam-Induced Sensitization to Withdrawal Signs in Mice
Neurotoxicity Research (2018)
-
GABAA Receptor Density Is Not Altered by a Novel Herbal Anxiolytic Treatment
Journal of Molecular Neuroscience (2018)
-
Role of GABAA receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model
Molecular Brain (2017)
-
Differential effects of short- and long-term zolpidem treatment on recombinant α1β2γ2s subtype of GABAA receptors in vitro
Acta Pharmacologica Sinica (2012)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
